Tulisokibart met its primary endpoint in a Phase 2b trial in hidradenitis suppurativa (HS), according to Dermatology Times — an early but consequential readout for a disease where biologic options remain limited and treatment response is often partial at best.

The announcement concerns a Phase 2b design, meaning the candidate has now cleared the dose-finding stage that typically determines which regimen advances to pivotal Phase 3 testing. Dermatology Times did not report secondary-endpoint figures, dosing arms, or responder rates alongside the headline result, so the size of the effect remains undisclosed pending fuller data presentation or publication.

Why the mechanism matters for HS

HS is a chronic inflammatory follicular disease driven substantially by tumor necrosis factor (TNF) and interleukin-17/23 signaling pathways. Currently, adalimumab — an anti-TNF monoclonal antibody — is the best-established biologic for moderate-to-severe HS, with secukinumab (anti-IL-17A) approved more recently. A new anti-TNF agent such as tulisokibart entering late-stage development signals manufacturers still see room to improve on first-generation TNF blockade, whether through engineered binding properties, dosing convenience, or efficacy margins in patients who respond inadequately to existing therapy.

The condition itself imposes a heavy burden. Moderate-to-severe HS presents with painful nodules, abscesses, and tunneling lesions in intertriginous areas, and it drives measurable reductions in quality-of-life scores that often exceed those seen in psoriasis. Hurley stage II–III patients frequently cycle through antibiotics, surgery, and off-label therapies before finding durable control.

What the Phase 2b result does and does not establish

Meeting a primary endpoint in Phase 2b establishes a proof-of-concept signal robust enough, in the sponsor's judgment, to justify continued development. It does not establish regulatory approvability, safety at scale, or comparative performance against adalimumab. For dermatologists, the practical questions that will determine tulisokibart's eventual place in practice include:

• Effect size on HS clinical response endpoints, such as HiSCR50/HiSCR75, versus placebo
• Durability of response beyond the induction window
• Safety profile relative to existing TNF inhibitors
• Dosing interval and route, which shape real-world adherence

None of those specifics appear in the initial report, so clinicians should treat the endpoint success as directional rather than practice-changing.

The competitive backdrop

The HS pipeline has widened considerably as sponsors look beyond psoriasis indications. Bimekizumab, an IL-17A/F inhibitor, and several IL-17 and JAK-family candidates have posted mid-stage HS data in recent years, and secukinumab's approval added a second mechanism to the approved arsenal. A Phase 2b success for tulisokibart keeps anti-TNF biology competitive within that field rather than ceding the mechanism entirely to older agents.

For payers and prescribers, more HS biologics would mean more therapeutic sequencing options — a meaningful consideration given that a substantial share of adalimumab-treated patients do not reach high-tier response criteria.

What comes next

The standard trajectory after a positive Phase 2b readout is presentation of full results at a congress such as the AAD annual meeting or EADV, followed by peer-reviewed publication and Phase 3 initiation. Dermatology Times' report confirms only the endpoint success itself; the trial's sponsor will determine how quickly detailed efficacy and safety data reach the public record.

Dermatologists managing moderate-to-severe HS should watch for the full dataset — particularly HiSCR responder curves and injection-frequency data — as tulisokibart moves toward pivotal trials that could eventually add a new anti-TNF option to a still-thin treatment armamentarium.